INTRODUCTION: The aim of this work was to follow prospectively a cohort of patients suffering from neurogenic overactive bladder, treated by botulinum toxin A, study the efficiency of this treatment, analyse the primary failures, secondary and surrender.
PATIENTS AND METHODS: Thirty-one patients suffering from neurogenic OAB received a detrusor injection of 300 units of Botox™ (ALLERGAN, Irvine, CA) and were followed prospectively (median 5 years). They were evaluated by voiding diary, Qualiveen™ questionnary and urodynamics before treatment, 2 months after the first injection and the last re-injection.
RESULTS: Five years after the beginning of the treatment, 17 patients of 31 (54.8%) were still injected, it means 60.7% of the primary responders. Eleven patients had left up the treatment, after at least one effective injection. We identified three reasons of surrender: echapment of treatment for two patients of 11 (7.1%); cessation of self catheterize for six patients of 11 (54.6%) and the surrender of the treatment without clinical or urodynamical failure, for three patients of 11 (27.3%). Although the cessation of self catheterize was more frequent for patients suffering from multiple sclerosis, no predictive factor of surrender was statically significant.
CONCLUSION: In this series, bladder BTA injections was efficient at middle term to treat neurogenic OAB. The echapment was a rare event (7%). The major cause of surrender was the increase difficulty to self catheterize, due to progression of disability, more frequent for patients suffering of multiple sclerosis.
Written by:
Gaillet S, Bardot P, Bernuz B, Boissier R, Lenne-Aurier K, Thiry-Escudier I, Tournebise H, Lechevallier E, Karsenty G. Are you the author?
Aix Marseille université, 13284, Marseille, France; AP-HM, La Conception hospital, urology and kidney transplantation, 13385 Marseille, France.
Reference: Prog Urol. 2012 Dec;22(17):1064-70.
doi: 10.1016/j.purol.2012.10.006
PubMed Abstract
PMID: 23182121
UroToday.com Overactive Bladder (OAB) Section
